GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Establishment Labs Holdings Inc (NAS:ESTA) » Definitions » Cash Ratio

Establishment Labs Holdings (Establishment Labs Holdings) Cash Ratio : 0.70 (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Establishment Labs Holdings Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Establishment Labs Holdings's Cash Ratio for the quarter that ended in Dec. 2023 was 0.70.

Establishment Labs Holdings has a Cash Ratio of 0.70. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.

The historical rank and industry rank for Establishment Labs Holdings's Cash Ratio or its related term are showing as below:

ESTA' s Cash Ratio Range Over the Past 10 Years
Min: 0.01   Med: 1.65   Max: 3.26
Current: 0.7

During the past 8 years, Establishment Labs Holdings's highest Cash Ratio was 3.26. The lowest was 0.01. And the median was 1.65.

ESTA's Cash Ratio is ranked worse than
63.67% of 856 companies
in the Medical Devices & Instruments industry
Industry Median: 1.25 vs ESTA: 0.70

Establishment Labs Holdings Cash Ratio Historical Data

The historical data trend for Establishment Labs Holdings's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Establishment Labs Holdings Cash Ratio Chart

Establishment Labs Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Ratio
Get a 7-Day Free Trial 1.62 3.26 1.68 1.70 0.70

Establishment Labs Holdings Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.70 1.03 2.08 1.04 0.70

Competitive Comparison of Establishment Labs Holdings's Cash Ratio

For the Medical Devices subindustry, Establishment Labs Holdings's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Establishment Labs Holdings's Cash Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Establishment Labs Holdings's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Establishment Labs Holdings's Cash Ratio falls into.



Establishment Labs Holdings Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Establishment Labs Holdings's Cash Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash Ratio (A: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=40.035/57.15
=0.70

Establishment Labs Holdings's Cash Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash Ratio (Q: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=40.035/57.15
=0.70

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Establishment Labs Holdings  (NAS:ESTA) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Establishment Labs Holdings Cash Ratio Related Terms

Thank you for viewing the detailed overview of Establishment Labs Holdings's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Establishment Labs Holdings (Establishment Labs Holdings) Business Description

Traded in Other Exchanges
Address
Coyol Free Zone, Building B15 and 25, Alajuela, CRI
Establishment Labs Holdings Inc is a medical technology company engaged in offering medical devices and aesthetic products. It is involved in designing, manufacturing, and marketing silicone-filled breast and body shaping implants. The company markets its products under Motiva implants Brand. It distributes its products to medical distributors; and physicians, hospitals, and clinics in the form of direct sales. Its geographical segments are Europe, Latin America, Asia-Pacific/Middle East, and Others.
Executives
Nicholas Sheridan Lewin director, 10 percent owner 3 WEST 57TH ST., 8TH FLOOR, NEW YORK NY 10019
Raj Denhoy officer: Chief Financial Officer C/O MOTIVA USA, LLC, 16192 COASTAL HIGHWAY, LEWES DE 19958
Dennis E Condon director 811 ALSTON RD, SANTA BARBARA CA 93108
Leslie Gillin director C/O MOTIVA USA, LLC, 16192 COASTAL HIGHWAY, LEWES DE 19958
Paul D. Rodio officer: Chief Operating Officer C/O MOTIVA USA LLC, 16192 COASTAL HIGHWAY, LEWES DE 19958
Samuel Ross Mansbach other: GC & Chief Compliance Officer C/O MOTIVA USA LLC, 16192 COASTAL HIGHWAY, LEWES DE 19958
Jw Asset Management, Llc 10 percent owner, other: See Footnote(1) 1051 N VENETIAN DRIVE, MIAMI BEACH FL 33139
Bryan Slotkin director C/O MOTIVA USA,.LLC, 16192 COASTAL HIGHWAY, LEWES DE 19958
Ann Custin director C/O MOTIVA USA, LLC, 16192 COASTAL HIGHWAY, LEWES DE 19958
Edward J Schutter director C/O FIRST HORIZON PHARMACEUTICAL CORP, 6195 SHILOH ROAD, ALPHARETTA GA 30005
Lisa Gersh director C/O HASBRO, INC., 1011 NEWPORT AVENUE, PAWTUCKET RI 02861
Mezerville Roberto De officer: Chief Technology Officer C/O MOTIVA USA LLC, 16192 COASTAL HIGHWAY, LEWES DE 19958
Renee Gaeta officer: Chief Financial Officer C/O MOTIVA USA LLC, 16192 COASTAL HIGHWAY, LEWES DE 19958
Pratip Dastidar officer: Head of Global Operations 150 PEABODY PLACE, MEMPHIS TN 38103
Santos Salvador Dada officer: Chief Operating Officer C/O MOTIVA USA LLC, 16192 COASTAL HIGHWAY, LEWES DE 19958

Establishment Labs Holdings (Establishment Labs Holdings) Headlines